Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.42 |
| ▸ | FABP7 | O15540 | 2/20 | 0.42 |
| ▸ | CASP3 | P42574 | 2/20 | 0.40 |
| ▸ | ALB | P02768 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19198322 | 0.93 | ALB (0.34) | CA1CA2EPHX2KMT2AFABP5 | |
| SCHEMBL1539602 | 0.87 | CA1 (0.47) | CA1CA2EPHX2KMT2AFABP5 | |
| SCHEMBL17664205 | 0.85 | EPHX2 (0.36) | CA1CA2EPHX2KMT2AFABP5 | |
| SCHEMBL1934603 | 0.85 | KMT2A (0.43) | CA1CA2EPHX2KMT2AFABP5 | |
| SCHEMBL16253852 | 0.84 | KMT2A (0.48) | CA1CA2EPHX2KMT2AFABP5 | |
| SCHEMBL29349891 | 0.83 | KMT2A (0.55) | CA1CA2EPHX2KMT2AFABP5 | |
| SCHEMBL27547 | 0.83 | KMT2A (0.55) | CA1CA2EPHX2KMT2AFABP5 | |
| Hydrochloric Acid SCHEMBL810434 | 0.82 | KMT2A (0.54) | CA1CA2EPHX2KMT2AFABP5 | |
| Ammonia Solution, Strong SCHEMBL27794450 | 0.82 | KMT2A (0.54) | CA1CA2EPHX2KMT2AFABP5 | |
| SCHEMBL29178041 | 0.81 | CA1 (0.39) | CA1CA2EPHX2KMT2AFABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099917-A1 | Novel inhibitors and methods for their preparation | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2007-05-03 | — | — | US | claimed |
| EP-1761554-A2 | PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME | Biosource Pharm, Inc. (US) | 2007-03-14 | — | — | EP | claimed |
| WO-2006083317-A2 | PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME | BIOSOURCE PHARM, INC. (US) | 2006-08-10 | — | — | WO | claimed |
| WO-2016050764-A1 | METHOD FOR PEPTIDE SYNTHESIS AND APPARATUS FOR CARRYING OUT A METHOD FOR SOLID PHASE SYNTHESIS OF PEPTIDES | Technische Universität Darmstadt (DE) | 2016-04-07 | — | — | WO | disclosed |
| US-8937040-B2 | Antibiotic compositions for the treatment of gram negative infections | BIOSOURCE PHARM, INC. (US) | 2015-01-20 | — | — | US | disclosed |
| US-8906866-B2 | Antibiotic compositions for the treatment of gram negative infections | BIOSOURCE PHARM, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8889826-B2 | Peptide antibiotics and methods for making same | BIOSOURCE PHARM, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140073559-A1 | Antibiotic Compositions for the Treatment of Gram Negative Infections | CUBIST PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20130345121-A1 | Antibiotic Compositions For The Treatment of Gram Negative Infections | BIOSOURCE PHARM, INC. (US) | 2013-12-26 | — | — | US | disclosed |
| US-8415307-B1 | Antibiotic compositions for the treatment of gram negative infections | BIOSOURCE PHARM, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-8343912-B2 | Antibiotic compositions for the treatment of gram negative infections | BIOSOURCE PHARM, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| EP-2332965-A1 | Peptide antibiotics and methods for making same | BioSource Pharm, Inc. (US) | 2011-06-15 | — | — | EP | disclosed |
| US-20100160215-A1 | ANTIBIOTIC COMPOSITIONS FOR THE TREATMENT OF GRAM NEGATIVE INFECTIONS | BIOSOURCE PHARM, INC. | 2010-06-24 | — | — | US | disclosed |
| US-20070099917-A1 | Novel inhibitors and methods for their preparation | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2007-05-03 | — | — | US | disclosed |
| WO-2006083317-A9 | PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME | BIOSOURCE PHARM INC (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20060004185-A1 | Peptide antibiotics and peptide intermediates for their prepartion | BIOSOURCE PHARM, INC. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099917-A1 | Novel inhibitors and methods for their preparation | TK1, ABL1, FLT3 | CA1 2277/4885CA2 2445/4885EPHX2 854/4885 |
| US-20130345121-A1 | Antibiotic Compositions For The Treatment of Gram Negative Infections | PSMB7, MDN1, PSMB6 | CA1 4874/4885CA2 4850/4885EPHX2 4619/4885 |
| US-20060004185-A1 | Peptide antibiotics and peptide intermediates for their prepartion | PREP, VIP, PEPD | CA1 4436/4885CA2 4539/4885EPHX2 4780/4885 |
| US-20140073559-A1 | Antibiotic Compositions for the Treatment of Gram Negative Infections | RPN2, NRDC, RPN1 | CA1 4871/4885CA2 4776/4885EPHX2 4681/4885 |
| US-20100160215-A1 | ANTIBIOTIC COMPOSITIONS FOR THE TREATMENT OF GRAM NEGATIVE INFECTIONS | PSMB7, IL17A, IL1B | CA1 4878/4885CA2 4856/4885EPHX2 4260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.